Reboxetine combination Therapy with Fluoxetine in the treatment of obsessive-compulsive disorder

Reboxetine combination therapy with Fluoxetine in the treatment of moderate to severe obsessive-compulsive disorder: A randomized double blind and placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N129

Enrollment

Registered

2020-05-20

Start date

2020-07-10

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Fluoxetine tablet (Abidi co.) 80 mg once per day + Reboxetine (Pfizer co.) tablet 10 mg BID, for 10 weeks. Intervention 2: Control group: Fluoxetine tablet (Abidi c

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 60 years Diagnosis of moderate to severe OCD based on DSM-5 Score of >21 in Yale–Brown obsessive-compulsive scale (Y-BOCS)

Exclusion criteria

Exclusion criteria: Receiving any treatment up to 6 weeks before the start of the trial Presence of another psychiatric disorder

Design outcomes

Primary

Measure	Time frame
Severity of OCD symptoms. Timepoint: Baseline and weeks 5 and 10. Method of measurement: By Yale–Brown obsessive-compulsive scale (Y-BOCS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026